Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)
July 18, 2014 08:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, July 18, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that DALVANCE (dalbavancin) for injection is now available for use to treat adult patients with acute...
Durata Therapeutics to Present at Upcoming Investor Conferences
June 17, 2014 09:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, June 17, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that members of the executive team will participate in three upcoming investor conferences.
Paul R....
New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program
June 04, 2014 17:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, June 4, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the Phase 3 data from its DISCOVER program evaluating dalbavancin for the treatment of acute bacterial...
FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults
May 23, 2014 16:17 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 23, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved DALVANCETM (dalbavancin) for injection...
Durata Therapeutics Presents Six Dalbavancin Posters at the 24th Annual ECCMID Meeting
May 13, 2014 16:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 13, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, was presented...
Durata Therapeutics to Present at Upcoming Investor Conferences
May 09, 2014 08:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 9, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will be presenting an overview of the Company at two upcoming investor...
Durata Therapeutics Reports First Quarter 2014 Financial Results
May 08, 2014 07:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 8, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended March 31, 2014.
"The first quarter of 2014 ended on a high...
Durata Therapeutics to Present Six Dalbavancin Posters at the 24th Annual ECCMID Meeting
May 02, 2014 08:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 2, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be...
Durata Therapeutics to Announce First Quarter 2014 Financial Results on May 8, 2014
May 01, 2014 08:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, May 1, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, May 8 at 8:30 a.m. Eastern Time to discuss first quarter 2014...
Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance(TM) in a 1500 mg Single Dose
April 24, 2014 08:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, April 24, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it has initiated enrollment of a Phase 3b clinical trial to evaluate the efficacy and safety of...